Literature DB >> 15925493

Size of burden of schizophrenia and psychotic disorders.

Wulf Rössler1, Hans Joachim Salize, Jim van Os, Anita Riecher-Rössler.   

Abstract

Schizophrenia is a severe mental disorder characterised by fundamental disturbances in thinking, perception and emotions. More than 100 years of research have not been able to fully resolve the puzzle that schizophrenia represents. Even if schizophrenia is not a very frequent disease, it is among the most burdensome and costly illnesses worldwide. It usually starts in young adulthood. Life expectancy is reduced by approximately 10 years, mostly as a consequence of suicide. Even if the course of the illness today is considered more favourable than it was originally described, it is still only a minority of those affected, who fully recover. The cumulative lifetime risk for men and women is similar, although it is higher for men in the age group younger than 40 years. According to the Global Burden of Disease Study, schizophrenia causes a high degree of disability, which accounts for 1.1% of the total DALYs (disability-adjusted life years) and 2.8% of YLDs (years lived with disability). In the World Health Report [The WHO World Health Report: new understanding, new hope, 2001. Geneva], schizophrenia is listed as the 8th leading cause of DALYs worldwide in the age group 15-44 years. In addition to the direct burden, there is considerable burden on the relatives who care for the sufferers. The treatment goals for the moment are to identify the illness as early as possible, treat the symptoms, provide skills to patients and their families, maintain the improvement over a period of time, prevent relapses and reintegrate the ill persons into the community so that they can lead as normal a life as possible.

Entities:  

Mesh:

Year:  2005        PMID: 15925493     DOI: 10.1016/j.euroneuro.2005.04.009

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  147 in total

1.  Prediction and prevention of schizophrenia: what has been achieved and where to go next?

Authors:  Joachim Klosterkötter; Frauke Schultze-Lutter; Andreas Bechdolf; Stephan Ruhrmann
Journal:  World Psychiatry       Date:  2011-10       Impact factor: 49.548

2.  Early psychological interventions for psychosis.

Authors:  Susana Ochoa; Raquel López-Carrilero
Journal:  World J Psychiatry       Date:  2015-12-22

3.  Conceptualization and treatment of negative symptoms in schizophrenia.

Authors:  Sonali Sarkar; Kiley Hillner; Dawn I Velligan
Journal:  World J Psychiatry       Date:  2015-12-22

Review 4.  From early intervention in psychosis to youth mental health reform: a review of the evolution and transformation of mental health services for young people.

Authors:  Ashok Malla; Srividya Iyer; Patrick McGorry; Mary Cannon; Helen Coughlan; Swaran Singh; Peter Jones; Ridha Joober
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-12-19       Impact factor: 4.328

5.  Subjective quality of life of patients with obsessive-compulsive disorder.

Authors:  Katarina Stengler-Wenzke; Michael Kroll; Herbert Matschinger; Matthias C Angermeyer
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2006-05-23       Impact factor: 4.328

6.  Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.

Authors:  Annemieke De Ridder; Diana De Graeve
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

7.  Subclinical psychosis syndromes in the general population: results from a large-scale epidemiological survey among residents of the canton of Zurich, Switzerland.

Authors:  W Rössler; V Ajdacic-Gross; H Haker; S Rodgers; M Müller; M P Hengartner
Journal:  Epidemiol Psychiatr Sci       Date:  2013-11-26       Impact factor: 6.892

8.  Schizotypal personality disorder in individuals with the Attenuated Psychosis Syndrome: Frequent co-occurrence without an increased risk for conversion to threshold psychosis.

Authors:  Anthony W Zoghbi; Joel A Bernanke; Julia Gleichman; Michael D Masucci; Cheryl M Corcoran; Allegra Califano; Justin Segovia; Tiziano Colibazzi; Michael B First; Gary Brucato; Ragy R Girgis
Journal:  J Psychiatr Res       Date:  2019-04-21       Impact factor: 4.791

9.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

10.  Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.

Authors:  Simon Frey; Roland Linder; Georg Juckel; Tom Stargardt
Journal:  Eur J Health Econ       Date:  2013-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.